<p>根据 MarketBeat.com 的报道，Eli Lilly and Company（纽约证券交易所代码：LLY - 获取免费报告）的股票获得了目前覆盖该公司的 19 家评级公司的平均评级为 “适度买入”。两名股票研究分析师对该股票给予了持有评级，十七名分析师对该公司发布了买入评级。在过去一年中，覆盖该股票的经纪公司平均 12 个月的目标价为 1,017.67 美元。</p>
<p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
<ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
<p>最近，一些股票分析师对 LLY 股票发表了看法。Berenberg Bank 在 1 月 16 日的研究报告中将 Eli Lilly and Company 的股票目标价设定为 970.00 美元。摩根士丹利在周三将 Eli Lilly and Company 的目标价从 1,146.00 美元下调至 1,124.00 美元，并对该公司给予了 “增持” 评级。Truist Financial 在 2 月 3 日的报告中将 Eli Lilly and Company 的目标价从 1,029.00 美元提高至 1,038.00 美元，并给予该股票 “买入” 评级。富国银行在 3 月 5 日的研究报告中将 Eli Lilly and Company 的目标价从 970.00 美元提高至 1,100.00 美元，并给予该股票 “增持” 评级。最后，高盛集团在周二将 Eli Lilly and Company 的股票评级从 “中性” 上调至 “买入”，并将该公司的目标价从 892.00 美元下调至 888.00 美元。</p>
<p><strong>查看我们对 Eli Lilly and Company 的最新分析</strong></p>
<h2>内部人士下注</h2>
<ul>
<li>目标价显示这 3 只股票接近 1 万亿美元的标志</li>
</ul>
<p>在其他新闻中，首席会计官 Donald A. Zakrowski 在 3 月 13 日的交易中出售了 1,000 股公司的股票。该股票以 818.24 美元的平均价格出售，总交易额为 818,240.00 美元。出售后，首席会计官现在直接持有该公司 5,840 股股票，价值约为 4,778,521.60 美元。此次交易使其持股减少了 14.62%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。公司内部人士持有公司股票的 0.13%。</p>
<h2>机构投资者对 Eli Lilly and Company 的看法</h2>
<p>几家机构投资者和对冲基金最近买卖了该公司的股票。GAMMA Investing LLC 在第一季度将其在 Eli Lilly and Company 的持仓提高了 103,831.6%。GAMMA Investing LLC 现在拥有 14,866,380 股该公司的股票，价值为 12,278,292,000 美元，此前在上一季度购买了额外的 14,852,076 股。挪威银行在第四季度获得了 Eli Lilly and Company 的新头寸，价值约为 8,407,908,000 美元。Proficio Capital Partners LLC 在第四季度将其在 Eli Lilly and Company 的持仓提高了 100,387.1%。Proficio Capital Partners LLC 现在拥有 5,202,215 股该公司的股票，价值为 4,016,110,000 美元，此前在该期间购买了额外的 5,197,038 股。Wellington Management Group LLP 在第四季度将其在 Eli Lilly and Company 的股份提高了 19.0%。Wellington Management Group LLP 现在拥有 12,625,925 股该公司的股票，价值为 9,747,214,000 美元，此前在上一季度购买了额外的 2,012,129 股。最后，Capital International Investors 在第四季度将其在 Eli Lilly and Company 的持仓提高了 23.2%。Capital International Investors 现在拥有 8,730,758 股该公司的股票，价值为 6,740,272,000 美元，此前在该期间获得了额外的 1,645,222 股。机构投资者持有公司 82.53% 的股票。</p>
<h2>Eli Lilly and Company 股票下跌 4.5%</h2>
<ul>
<li>AbbVie 股票通过进入减肥市场提升投资组合</li>
</ul>
<p>Eli Lilly and Company 的股票在周五开盘价为 719.85 美元。Eli Lilly and Company 的 1 年最低价为 677.09 美元，1 年最高价为 972.53 美元。该公司的市值为 6825.4 亿美元，市盈率为 61.47，市盈增长比率为 1.40，贝塔值为 0.51。该公司的流动比率为 1.15，速动比率为 0.97，债务与股本比率为 2.00。该股票的 50 日移动平均价格为 838.96 美元，200 日移动平均价格为 824.81 美元。</p>
<p>Eli Lilly and Company（纽约证券交易所代码：LLY - 获取免费报告）最近在 2 月 6 日发布了季度财报。该公司报告每股收益（EPS）为 5.32 美元，低于分析师一致预期的 5.45 美元，差额为 0.13 美元。Eli Lilly and Company 的股本回报率为 85.24%，净利润率为 23.51%。整体来看，分析师预计 Eli Lilly and Company 在当前财政年度将发布 23.48 美元的每股收益。</p>
<h2>Eli Lilly and Company 公司简介</h2>
<p>（获取免费报告）</p>
<p>Eli Lilly and Company 在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票比 Eli Lilly and Company 更好</li>
<li>交易暂停解释</li>
<li>Joby Aviation：运营势头与市场情绪的对比</li>
<li>3 只 REITs 值得长期买入和持有</li>
<li>博通的强劲表现显示出关税下降中的韧性</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>Carvana：能否通过强劲的转机超越市场逆风？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>礼来公司（NYSE: LLY）获得了 19 家券商的 “适度买入” 平均评级。分析师设定的 12 个月价格目标平均为 1,017.67 美元，其中包括两项持有评级和十七项买入评级。最近的价格目标包括来自贝伦贝格银行的 970.00 美元和来自富国银行的 1,100.00 美元。该股票开盘价为 719.85 美元，1 年最低价为 677.09 美元，最高价为 972.53 美元。机构投资者持有该公司 82.53% 的股份，礼来在上个季度报告的每股收益为 5.32 美元，低于预期 0.13 美元</p>

<p>Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) have received an average rating of &#34;Moderate Buy&#34; from the nineteen ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $1,017.67.</p>
<div class="lb-trans"><p>根据 MarketBeat.com 的报道，Eli Lilly and Company（纽约证券交易所代码：LLY - 获取免费报告）的股票获得了目前覆盖该公司的 19 家评级公司的平均评级为 “适度买入”。两名股票研究分析师对该股票给予了持有评级，十七名分析师对该公司发布了买入评级。在过去一年中，覆盖该股票的经纪公司平均 12 个月的目标价为 1,017.67 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
</div><p>A number of equities analysts have recently weighed in on LLY shares. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Morgan Stanley lowered their price target on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday. Truist Financial increased their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, February 3rd. Wells Fargo &amp; Company boosted their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an &#34;overweight&#34; rating in a research report on Wednesday, March 5th. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and cut their price target for the company from $892.00 to $888.00 in a report on Tuesday.</p>
<div class="lb-trans"><p>最近，一些股票分析师对 LLY 股票发表了看法。Berenberg Bank 在 1 月 16 日的研究报告中将 Eli Lilly and Company 的股票目标价设定为 970.00 美元。摩根士丹利在周三将 Eli Lilly and Company 的目标价从 1,146.00 美元下调至 1,124.00 美元，并对该公司给予了 “增持” 评级。Truist Financial 在 2 月 3 日的报告中将 Eli Lilly and Company 的目标价从 1,029.00 美元提高至 1,038.00 美元，并给予该股票 “买入” 评级。富国银行在 3 月 5 日的研究报告中将 Eli Lilly and Company 的目标价从 970.00 美元提高至 1,100.00 美元，并给予该股票 “增持” 评级。最后，高盛集团在周二将 Eli Lilly and Company 的股票评级从 “中性” 上调至 “买入”，并将该公司的目标价从 892.00 美元下调至 888.00 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Eli Lilly and Company 的最新分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>Price Targets Show These 3 Stocks Near the $1 Trillion Mark</li>
</ul>
<div class="lb-trans"><ul>
<li>目标价显示这 3 只股票接近 1 万亿美元的标志</li>
</ul>
</div><p>In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.13% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席会计官 Donald A. Zakrowski 在 3 月 13 日的交易中出售了 1,000 股公司的股票。该股票以 818.24 美元的平均价格出售，总交易额为 818,240.00 美元。出售后，首席会计官现在直接持有该公司 5,840 股股票，价值约为 4,778,521.60 美元。此次交易使其持股减少了 14.62%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。公司内部人士持有公司股票的 0.13%。</p>
</div><h2>Institutional Investors Weigh In On Eli Lilly and Company</h2>
<div class="lb-trans"><h2>机构投资者对 Eli Lilly and Company 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $8,407,908,000. Proficio Capital Partners LLC lifted its position in shares of Eli Lilly and Company by 100,387.1% during the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock worth $4,016,110,000 after buying an additional 5,197,038 shares during the period. Wellington Management Group LLP boosted its stake in Eli Lilly and Company by 19.0% in the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after buying an additional 2,012,129 shares in the last quarter. Finally, Capital International Investors grew its position in Eli Lilly and Company by 23.2% in the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after acquiring an additional 1,645,222 shares during the period. Institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买卖了该公司的股票。GAMMA Investing LLC 在第一季度将其在 Eli Lilly and Company 的持仓提高了 103,831.6%。GAMMA Investing LLC 现在拥有 14,866,380 股该公司的股票，价值为 12,278,292,000 美元，此前在上一季度购买了额外的 14,852,076 股。挪威银行在第四季度获得了 Eli Lilly and Company 的新头寸，价值约为 8,407,908,000 美元。Proficio Capital Partners LLC 在第四季度将其在 Eli Lilly and Company 的持仓提高了 100,387.1%。Proficio Capital Partners LLC 现在拥有 5,202,215 股该公司的股票，价值为 4,016,110,000 美元，此前在该期间购买了额外的 5,197,038 股。Wellington Management Group LLP 在第四季度将其在 Eli Lilly and Company 的股份提高了 19.0%。Wellington Management Group LLP 现在拥有 12,625,925 股该公司的股票，价值为 9,747,214,000 美元，此前在上一季度购买了额外的 2,012,129 股。最后，Capital International Investors 在第四季度将其在 Eli Lilly and Company 的持仓提高了 23.2%。Capital International Investors 现在拥有 8,730,758 股该公司的股票，价值为 6,740,272,000 美元，此前在该期间获得了额外的 1,645,222 股。机构投资者持有公司 82.53% 的股票。</p>
</div><h2>Eli Lilly and Company Stock Down 4.5 %</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 股票下跌 4.5%</h2>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 股票通过进入减肥市场提升投资组合</li>
</ul>
</div><p>Shares of Eli Lilly and Company stock opened at $719.85 on Friday. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a market cap of $682.54 billion, a P/E ratio of 61.47, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock has a 50-day moving average price of $838.96 and a 200 day moving average price of $824.81.</p>
<div class="lb-trans"><p>Eli Lilly and Company 的股票在周五开盘价为 719.85 美元。Eli Lilly and Company 的 1 年最低价为 677.09 美元，1 年最高价为 972.53 美元。该公司的市值为 6825.4 亿美元，市盈率为 61.47，市盈增长比率为 1.40，贝塔值为 0.51。该公司的流动比率为 1.15，速动比率为 0.97，债务与股本比率为 2.00。该股票的 50 日移动平均价格为 838.96 美元，200 日移动平均价格为 824.81 美元。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Eli Lilly and Company（纽约证券交易所代码：LLY - 获取免费报告）最近在 2 月 6 日发布了季度财报。该公司报告每股收益（EPS）为 5.32 美元，低于分析师一致预期的 5.45 美元，差额为 0.13 美元。Eli Lilly and Company 的股本回报率为 85.24%，净利润率为 23.51%。整体来看，分析师预计 Eli Lilly and Company 在当前财政年度将发布 23.48 美元的每股收益。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 公司简介</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>Eli Lilly and Company 在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Trading Halts Explained</li>
<li>Joby Aviation: Operational Momentum vs. Market Sentiment</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>Broadcom's Big Outperformance Shows Strength Amid Tariff Decline</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Carvana: Can Turnaround Strength Outdrive Market Headwinds?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Eli Lilly and Company 更好</li>
<li>交易暂停解释</li>
<li>Joby Aviation：运营势头与市场情绪的对比</li>
<li>3 只 REITs 值得长期买入和持有</li>
<li>博通的强劲表现显示出关税下降中的韧性</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>Carvana：能否通过强劲的转机超越市场逆风？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

礼来公司（NYSE:LLY）获得券商的 “适度买入” 平均评级